# A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

> **NCT05794581** · PHASE1 · COMPLETED · sponsor: **Carmot Therapeutics, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** CT-868
- **DRUG:** Placebo
- **DRUG:** Victoza

## Key facts

- **NCT ID:** NCT05794581
- **Lead sponsor:** Carmot Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-21
- **Primary completion:** 2024-03-06
- **Final completion:** 2024-04-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05794581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05794581, "A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05794581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*